Ex-Novartis Exec Rahman To Steer Clinical Sciences At Glenmark
Executive Summary
Dr. Mahboob Rahman, a former Novartis therapeutic area head for immunology in global clinical development, joins Glenmark at a key juncture as the Indian firm advances several key R&D assets including in immuno-oncology. “Portfolio prioritization” and bringing in the right talent rank high on Rahman’s immediate agenda, while a “fast-paced” environment appears to be among the key draws for his move.
You may also be interested in...
Onward Ho! Glenmark Strikes First Onco Asset Deal With China’s Harbour BioMed
Glenmark has sealed a licensing deal for its early stage immuno-oncology asset with China’s Harbour BioMed, opening up new possibilities around collaborations between the two Asian nations. The Indian firm appears upbeat about the prospects of building further on this new linkage.
Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA
With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.